Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral Flonoltinib Maleate in Patients With JAK Inhibitor Treatment-Naïve or Resistant Myelofibrosis

NCT07750574 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT07750574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral Flonoltinib Maleate in Patients With JAK Inhibitor Treatment-Naïve or Resistant Myelofibrosis
Lead sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2028
Enrollment
105 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, myelofibrosis (pmf), myelofibrosis due to and following polycythemia vera, myelofibrosis transformation in essential thrombocythemia, myelofibrosis with high molecular risk mutations, myelofibrosis with myeloid metaplasia, myelofibrosis, post et, myelofibrosis, post pv, myelofibrosis, primary, myelofibrosis; anemia, myelofibrosis，mf, myeloid metaplasia